Dose-dependent PK [General Sta­tis­tics]

posted by Helmut Homepage – Vienna, Austria, 2011-11-02 23:30 (5338 d 21:29 ago) – Posting: # 7590
Views: 9,735

Dear ElMaestro!

❝ At least for EU, I guess part of the story is to live with the BE-guideline's requirement "Assessment of linearity will consider whether differences in dose-adjusted AUC meet a criterion of ± 25%." which can be dealt with very simply.

❝ Perhaps your angle is different and that where the complexity comes in? I am eager to hear.


Yes. I’m aiming at a confirmatory study – not the stuff mentioned in the GL (“If you come up with some serious writing about the drug’s PK from the Library of Alexandria – whether it might be on parchment or papyrus – we accept that and you have to perform the study on the highest dose only.”)

❝ […] Cmax etc vs dose being a straight line, I am perfectly willing to call that linearity;


I’m not happy with assessing dose-proportionality based on Cmax. It’s a f**g composite metric.
I prefer AUC by far.

Wikipedia does an excellent job at confusing readers.


Yeah, that’s funny reading matter. Should read the talk-page as well.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,654 posts in 4,992 threads, 1,571 registered users;
115 visitors (0 registered, 115 guests [including 7 identified bots]).
Forum time: 22:00 CEST (Europe/Vienna)

The idea is to try and give all the information to help others
to judge the value of your contribution;
not just the information that leads to judgment
in one particular direction or another.    Richard Feynman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5